The Aims: The present study addresses the issue of enhanced apoptotic response to AZT following co-treatmentwith an NF-kB inhibitor. Main methods: To investigate this issue, different cell lines were assayed for susceptibility to AZT-mediated apoptosiswithout orwith the addition of theNF-kB inhibitor Bay-11-7085. For further investigation,U937 cellswere selected as good-responder cells to the combination treatment with 32 or 128 μM AZT, and 1 μM Bay-11-7085. Inhibition of NF-kB activation by Bay-11-7085 in cells treated with AZT was assayed through Western blot analysis of p65 expression and by EMSA. Involvement of themitochondrial pathway of apoptosis in mechanisms underlying the improved effect of AZT following Bay-11-7085 co-treatment, was evaluated by assaying the cytochrome c release and the mitochondrial membrane potential (MMP) status using the JC-1 dye. Moreover, the transcriptional activity of both anti- and pro-apoptotic genes in U937 cells after combination treatment was quantitatively evaluated through real-time PCR. Key findings: We found that the combined treatment induced high levels of cytochrome c release and of MMP collapse in association with evident changes in the expression of both anti- and pro-apoptotic genes of the Bcl-2 family. Overexpression of Bcl-2 significantly suppressed the sensitization of U937 cells to an enhanced apoptotic response to AZT following co-treatment with the NF-kB inhibitor. Significance: The new findings suggest that a combination regimen based on AZT plus an NF-kB inhibitor could represent a new chemotherapeutic tool for retrovirus-related pathologies.present study addresses the issue of enhanced apoptotic response to AZT following co-treatment with an NF-kB inhibitor.

Matteucci, C., Minutolo, A., Marino Merlo, F., Grelli, S., Frezza, C., Mastino, A., et al. (2015). Characterization of the enhanced apoptotic response to azidothymidine by pharmacological inhibition of NF-kB. LIFE SCIENCES, 127, 90-97 [10.1016/j.lfs.2015.01.038].

Characterization of the enhanced apoptotic response to azidothymidine by pharmacological inhibition of NF-kB.

MATTEUCCI, CLAUDIA;MINUTOLO, ANTONELLA;GRELLI, SANDRO;MACCHI, BEATRICE
2015

Abstract

The Aims: The present study addresses the issue of enhanced apoptotic response to AZT following co-treatmentwith an NF-kB inhibitor. Main methods: To investigate this issue, different cell lines were assayed for susceptibility to AZT-mediated apoptosiswithout orwith the addition of theNF-kB inhibitor Bay-11-7085. For further investigation,U937 cellswere selected as good-responder cells to the combination treatment with 32 or 128 μM AZT, and 1 μM Bay-11-7085. Inhibition of NF-kB activation by Bay-11-7085 in cells treated with AZT was assayed through Western blot analysis of p65 expression and by EMSA. Involvement of themitochondrial pathway of apoptosis in mechanisms underlying the improved effect of AZT following Bay-11-7085 co-treatment, was evaluated by assaying the cytochrome c release and the mitochondrial membrane potential (MMP) status using the JC-1 dye. Moreover, the transcriptional activity of both anti- and pro-apoptotic genes in U937 cells after combination treatment was quantitatively evaluated through real-time PCR. Key findings: We found that the combined treatment induced high levels of cytochrome c release and of MMP collapse in association with evident changes in the expression of both anti- and pro-apoptotic genes of the Bcl-2 family. Overexpression of Bcl-2 significantly suppressed the sensitization of U937 cells to an enhanced apoptotic response to AZT following co-treatment with the NF-kB inhibitor. Significance: The new findings suggest that a combination regimen based on AZT plus an NF-kB inhibitor could represent a new chemotherapeutic tool for retrovirus-related pathologies.present study addresses the issue of enhanced apoptotic response to AZT following co-treatment with an NF-kB inhibitor.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/07 - Microbiologia e Microbiologia Clinica
Settore BIO/14
English
Con Impact Factor ISI
AZT; Apoptosis; Bcl-2; Chemotherapy; NF-kB; Apoptosis; Apoptosis Regulatory Proteins; Cytochromes c; Genes, bcl-2; Humans; Membrane Potential, Mitochondrial; NF-kappa B; Nitriles; Phosphorylation; Reverse Transcriptase Inhibitors; Sulfones; Transcription Factor RelA; Tumor Cells, Cultured; U937 Cells; Zidovudine
Matteucci, C., Minutolo, A., Marino Merlo, F., Grelli, S., Frezza, C., Mastino, A., et al. (2015). Characterization of the enhanced apoptotic response to azidothymidine by pharmacological inhibition of NF-kB. LIFE SCIENCES, 127, 90-97 [10.1016/j.lfs.2015.01.038].
Matteucci, C; Minutolo, A; Marino Merlo, F; Grelli, S; Frezza, C; Mastino, A; Macchi, B
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Matteucciet alLifeScience2015.pdf

non disponibili

Descrizione: articolo principale
Licenza: Copyright dell'editore
Dimensione 851.19 kB
Formato Adobe PDF
851.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/113687
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 18
social impact